Open AccessSerum free light chains and multiple myeloma: Is it time to extend their application?
Author(s) -
Markovic Uros,
Leotta Valerio,
Tibullo Daniele,
Giubbolini Rachele,
Romano Alessandra,
Del Fabro Vittorio,
Parrinello Nunziatina Laura,
Cannizzaro Maria Teresa,
Di Raimondo Francesco,
Conticello Concetta
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2636
Subject(s) - medicine , multiple myeloma , immunoglobulin light chain , pathology , oncology , immunology , antibody
In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.